Our top pick for
Colfax Corporation is a specialty industrial machinery business based in the US. Colfax Corporation shares (CFX) are listed on the NYSE and all prices are listed in US Dollars. Colfax Corporation employs 16,200 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$66.72|
|52-week range||$59.15 - $94.03|
|50-day moving average||$69.00|
|200-day moving average||$77.90|
|Wall St. target price||$50.42|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$1.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-19)||N/A|
|1 month (2022-05-26)||N/A|
|3 months (2022-03-29)||63.53%|
|6 months (2021-12-26)||N/A|
|1 year (2021-06-30)||45.65%|
|2 years (2020-06-30)||139.14%|
|3 years (2019-06-28)||138.03%|
|5 years (2017-06-29)||0.21%|
Valuing Colfax Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Colfax Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Colfax Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Colfax Corporation shares trade at around 29x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Colfax Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0958. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Colfax Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Colfax Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $597.8 million.
The EBITDA is a measure of a Colfax Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$3.9 billion|
|Operating margin TTM||8.76%|
|Gross profit TTM||$1.6 billion|
|Return on assets TTM||2.66%|
|Return on equity TTM||2.39%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
We're not expecting Colfax Corporation to pay a dividend over the next 12 months.
Colfax Corporation's shares were split on a 1:3 basis on 4 April 2022. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Colfax Corporation shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Colfax Corporation shares which in turn could have impacted Colfax Corporation's share price.
Over the last 12 months, Colfax Corporation's shares have ranged in value from as little as $59.15 up to $94.028. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Colfax Corporation's is 2.1225. This would suggest that Colfax Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.